On August 29, the Policy Training Session on the Digital-Intelligent Transformation Development of the Pharmaceutical Industry, hosted by the China Association for Medical Devices Industry (CAMDI), was held in Beijing. Director General Dong Jiangping of the Department of Medical Device Regulation of the National Medical Products Administration (NMPA) attended the session and delivered important remarks. Fu Yinan, Deputy Head of the Pharmaceutical Development Division, Consumer Goods Industry Department of the Ministry of Industry and Information Technology (MIIT), and Wang Aihua, Deputy Chief Engineer of the China Academy of Information and Communications Technology (CAICT), attended the session. More than 100 people attended the session on site, including relevant responsible persons of the Information Center of NMPA and the drug regulatory authorities of Beijing, Liaoning, Anhui, and Henan, and heads of outstanding medical device manufacturing enterprises. Furthermore, over 230 responsible and regulatory personnel from drug regulatory authorities across provinces, municipalities, and autonomous regions nationwide participated online.
Jiang Deyuan, incoming President of CAMDI, stated in his address that the Implementation Plan for the Digital-Intelligent Transformation of the Pharmaceutical Industry (2025-2030), issued by MIIT and six other authorities, will deeply advance artificial intelligence (AI)'s empowerment of new industrialization, promote the deep integration of next-generation information technology with the pharmaceutical industry chain, accelerate the digital-intelligent transformation of the pharmaceutical industry, and drive the pharmaceutical industry's high-quality development. He noted that the high attention to this training session from MIIT and NMPA regarding the high-quality development of digital-intelligent transformation in the medical device industry was tremendous encouragement and support for CAMDI and all participating enterprise representatives, and CAMDI will continue to serve national strategies, industrial development, and regulatory needs as always, and work together with all sectors of society to promote the healthy development of the industry.
Director General Dong Jiangping of the Department of Medical Device Regulation of NMPA delivered important remarks at the session. She pointed out that the Opinions on Comprehensively Deepening the Reform of Regulation of Drugs and Medical Devices to Promote the High-quality Development of the Pharmaceutical Industry (GBF [2024] No. 53) issued by the General Office of the State Council specifically proposes promoting the deep integration of next-generation information technology with the pharmaceutical industry chain and supporting the digital-intelligent transformation of drug and medical device manufacturing enterprises. It is of great significance to deeply understand and grasp the guiding philosophy and overall arrangements of the Implementation Plan for the Digital-Intelligent Transformation of the Pharmaceutical Industry (2025-2030), build consensus across the industry, pool strengths, and jointly advance the digital-intelligent transformation, thereby achieving the high-quality development, high-level safety, and high-efficiency governance of China's medical device sector.
Wang Aihua, Deputy Chief Engineer of CAICT, delivered a keynote speech titled "Advancement Ideas for the Digital-Intelligent Transformation of the Pharmaceutical Industry," in which he authoritatively expounded the background and current status of digital-intelligent transformation in the pharmaceutical industry, provided a detailed interpretation of the Implementation Plan for the Digital-Intelligent Transformation of the Pharmaceutical Industry (2025-2030) policy, and presented CAICT's key work in the medical device field. Wang Chunyong, Chief Engineer of GE HealthCare Advanced Manufacturing Technology Center, China; Wei Hanying, General Manager of Industrial Management Department at Natong Technology Group and Plant Manager at Tianjin Zhengtian Medical Instrument Co., Ltd.; Xu Hanwei, Vice President of Digitalization at Siemens Healthineers; Han Jinxiong, Head of the Supply Chain Platform and Deputy General Manager of the Life Sciences Business Unit at Vazyme; Gao Xiayun, Head of the Information Technology Department at Micro-Tech (Nanjing); and Yang Guohua, Head of Product Digitalization Department at Shenzhen Mindray Bio-Medical, respectively presented and exchanged views on core topics such as digital-intelligent transformation practices and reflections, operations and management, and advanced factory certification practices.
The session provided an authoritative interpretation of the background and key content of the Implementation Plan for the Digital-Intelligent Transformation of the Pharmaceutical Industry (2025-2030), offered authoritative guidance and exchanges on the digital-intelligent transformation of the medical device industry, and received unanimous recognition and praise from participating leaders and representatives.
Jiang Deyuan, incoming President of CAMDI, stated in his address that the Implementation Plan for the Digital-Intelligent Transformation of the Pharmaceutical Industry (2025-2030), issued by MIIT and six other authorities, will deeply advance artificial intelligence (AI)'s empowerment of new industrialization, promote the deep integration of next-generation information technology with the pharmaceutical industry chain, accelerate the digital-intelligent transformation of the pharmaceutical industry, and drive the pharmaceutical industry's high-quality development. He noted that the high attention to this training session from MIIT and NMPA regarding the high-quality development of digital-intelligent transformation in the medical device industry was tremendous encouragement and support for CAMDI and all participating enterprise representatives, and CAMDI will continue to serve national strategies, industrial development, and regulatory needs as always, and work together with all sectors of society to promote the healthy development of the industry.
Director General Dong Jiangping of the Department of Medical Device Regulation of NMPA delivered important remarks at the session. She pointed out that the Opinions on Comprehensively Deepening the Reform of Regulation of Drugs and Medical Devices to Promote the High-quality Development of the Pharmaceutical Industry (GBF [2024] No. 53) issued by the General Office of the State Council specifically proposes promoting the deep integration of next-generation information technology with the pharmaceutical industry chain and supporting the digital-intelligent transformation of drug and medical device manufacturing enterprises. It is of great significance to deeply understand and grasp the guiding philosophy and overall arrangements of the Implementation Plan for the Digital-Intelligent Transformation of the Pharmaceutical Industry (2025-2030), build consensus across the industry, pool strengths, and jointly advance the digital-intelligent transformation, thereby achieving the high-quality development, high-level safety, and high-efficiency governance of China's medical device sector.
Wang Aihua, Deputy Chief Engineer of CAICT, delivered a keynote speech titled "Advancement Ideas for the Digital-Intelligent Transformation of the Pharmaceutical Industry," in which he authoritatively expounded the background and current status of digital-intelligent transformation in the pharmaceutical industry, provided a detailed interpretation of the Implementation Plan for the Digital-Intelligent Transformation of the Pharmaceutical Industry (2025-2030) policy, and presented CAICT's key work in the medical device field. Wang Chunyong, Chief Engineer of GE HealthCare Advanced Manufacturing Technology Center, China; Wei Hanying, General Manager of Industrial Management Department at Natong Technology Group and Plant Manager at Tianjin Zhengtian Medical Instrument Co., Ltd.; Xu Hanwei, Vice President of Digitalization at Siemens Healthineers; Han Jinxiong, Head of the Supply Chain Platform and Deputy General Manager of the Life Sciences Business Unit at Vazyme; Gao Xiayun, Head of the Information Technology Department at Micro-Tech (Nanjing); and Yang Guohua, Head of Product Digitalization Department at Shenzhen Mindray Bio-Medical, respectively presented and exchanged views on core topics such as digital-intelligent transformation practices and reflections, operations and management, and advanced factory certification practices.
The session provided an authoritative interpretation of the background and key content of the Implementation Plan for the Digital-Intelligent Transformation of the Pharmaceutical Industry (2025-2030), offered authoritative guidance and exchanges on the digital-intelligent transformation of the medical device industry, and received unanimous recognition and praise from participating leaders and representatives.